Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Learn more about:
Related Clinical Trial
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Dysport for the Treatment of OMD Validation of the Implantation of a New Electrode for the Treatment of Dystonia Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia D-Serine Treatment For Tardive Dyskinesia Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Levetiracetam Treatment of Tardive Dyskinesia The Assessment of Movement Disorders Utilizing Live Two-Way Video Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents Xenazine in Late Dyskinetic Syndrome With Neuroleptics Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia Melatonin Treatment for Tardive Dyskinesia in Schizophrenia Extract of Ginkgo Biloba and Tardive Dyskinesia Aim to Reduce Movements in Tardive Dyskinesia Reducing Involuntary Movements in Tardive Dyskinesia A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Pyridoxal Kinase Activity in Tardive Dyskinesia Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Piracetam for Treatment Tardive Dyskinesia Treatment of Tardive Dyskinesia With Galantamine Tardive Dyskinesia and Cognitive Function Safety and Efficacy of Pyridoxal 5′ -Phosphate in the Treatment of Tardive Dyskinesia Addressing Involuntary Movements in Tardive Dyskinesia Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia

Brief Title

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Official Title

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Brief Summary

      Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in
      outpatient psychiatry practices in the United States (US), as well as to describe the
      associated disease burden in a cohort of patients with one or more psychiatric disorders and
      a cumulative lifetime exposure to antipsychotic medication of three months or more.
    



Study Type

Observational [Patient Registry]


Primary Outcome

Customized clinician-reported outcomes


Condition

Tardive Dyskinesia


Study Arms / Comparison Groups

 Cohort 1
Description:  Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

70

Start Date

April 4, 2017

Completion Date

August 2018

Primary Completion Date

August 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patient has a cumulative lifetime exposure to antipsychotic medication of three months
             or more

          -  Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as
             defined in the DSM-5

          -  Patient has a usual care clinic visit scheduled during the study recruitment window
             (i.e. a pre-defined 2-week period)

          -  Patient is able to read and understand English

          -  Patient is willing and able to comply with the study requirements

        Exclusion Criteria:

          -  Patient is unable to provide informed consent.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Chris O'Brien, MD, 1-800-242-2196, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03062033

Organization ID

EVA-19350


Responsible Party

Sponsor

Study Sponsor

Neurocrine Biosciences

Collaborators

 Evidera

Study Sponsor

Chris O'Brien, MD, Study Director, Chief Medical Officer


Verification Date

November 2017